FRANCISCO
VANACLOCHA SEBASTIÁN
Researcher in the period 2009-2016
![Foto de FRANCISCO](/img/nophoto.png)
![Foto de Hospital General Universitario de Alicante](/img/noimage_org.png)
Hospital General Universitario de Alicante
Alicante, EspañaPublications in collaboration with researchers from Hospital General Universitario de Alicante (20)
2019
-
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364
2017
-
A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature
Actas Dermo-Sifiliograficas, Vol. 108, Núm. 2, pp. 168-170
-
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028
-
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321
-
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry
Actas dermo-sifiliograficas, Vol. 108, Núm. 1, pp. 52-58
-
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 52-58
-
Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort
British Journal of Dermatology
2016
-
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209
-
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950
-
Urine metabolome profiling of immune-mediated inflammatory diseases
BMC Medicine, Vol. 14, Núm. 1
2015
-
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
Actas Dermo-Sifiliograficas, Vol. 106, Núm. 8, pp. 638-643
-
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
Actas dermo-sifiliograficas, Vol. 106, Núm. 8, pp. 638-643
-
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 1, pp. 156-163
-
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: An observational study from national BIOBADADERM registry
Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 5, pp. 858-864
-
Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice
Journal of Dermatological Treatment, Vol. 26, Núm. 6, pp. 502-506
2014
-
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: Results of the Biobadaderm Registry
Journal of the European Academy of Dermatology and Venereology, Vol. 28, Núm. 7, pp. 907-914
2013
-
Guidelines for the use of acitretin in psoriasis
Actas Dermo-Sifiliograficas
-
Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry
Journal of the European Academy of Dermatology and Venereology, Vol. 27, Núm. 11, pp. 1366-1374
2012
-
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials
Archives of Dermatology, Vol. 148, Núm. 4, pp. 463-470
2010
-
Guidelines on the use of methotrexate in psoriasis
Actas Dermo-Sifiliograficas, Vol. 101, Núm. 7, pp. 600-613